AVLN

Avalyn Pharma Inc. AVLN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$2.12M

Quarter to Jun 30

Net income

$-28.93M

Quarter to Jun 30

Free cash flow

$-26.34M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.46B total
FMR LLC
$192.10M--
Novo Holdings A/S
$127.84M--
SR ONE CAPITAL MANAGEMENT, LP
$108.92M--
PERCEPTIVE ADVISORS LLC
$88.07M--
SUVRETTA CAPITAL MANAGEMENT, LLC
$82.40M--
NVP Associates, LLC
$74.68M--
WELLINGTON MANAGEMENT GROUP LLP
$72.49M--
PRICE T ROWE ASSOCIATES INC /MD/
$57.12M--
Catalio Capital Management, LP
$55.17M--
T. Rowe Price Investment Management, Inc.
$52.76M--
EVENTIDE ASSET MANAGEMENT, LLC
$45.28M--
Bellevue Group AG
$44.44M--
BlackRock, Inc.
$32.17M--
Pivotal bioVenture Partners Investment Advisor LLC
$31.83M--
CITADEL ADVISORS LLC
$31.57M--
Andera Partners
$30.61M--
JENNISON ASSOCIATES LLC
$26.76M--
BRAIDWELL LP
$26.38M--
TPG GP A, LLC
$25.45M--
VANGUARD CAPITAL MANAGEMENT LLC
$24.35M--
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$24.06M--
Rock Springs Capital Management LP
$21.82M--
GEODE CAPITAL MANAGEMENT, LLC
$14.31M--
Soleus Capital Management, L.P.
$13.79M--
INFINITUM ASSET MANAGEMENT, LLC
$13.54M--
See all 93 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AVLN

Earnings Per Share

13fpro.ai/company/AVLN

Loading ratio trend…

AVLN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Avalyn Pharma Inc. (AVLN): stock profile, AI score and financials

Avalyn Pharma Inc. (AVLN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AVLN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Avalyn Pharma Inc. reports quarterly revenue of $2.1M, net income of $-28.9M, free cash flow of $-26.3M. Top institutional holders of AVLN by reported 13-F value include FMR, Novo A/S, SR ONE CAPITAL MANAGEMENT, based on the most recent SEC filings. AVLN trades on the Nasdaq exchange and files with the SEC under CIK 1540171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalyn Pharma Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1540171 →